Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAmortizatization of IntangiblesAsset Writedowns and ImpairmentAsset Writedowns and ImpairmentCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in IntangiblesChange in InventoryChange in InventoryChange in ReceivablesChange in ReceivablesChange in TaxesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionExchange Rate EffectExchange Rate EffectFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesLong-Term Debt IssuancesNet Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesOther Working Capital ChangesOther financing activitiesOther financing activitiesShare-based CompensationShare-based CompensationShares IssuedShort-Term Debt issuancesShort-Term Debt repayments
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Myriad Genetics (MYGN) Gains from Sales and Divestitures (2016 - 2020)

Myriad Genetics has reported Gains from Sales and Divestitures over the past 6 years, most recently at $900000.0 for Q2 2020.

  • Quarterly Gains from Sales and Divestitures rose 12.5% to $900000.0 in Q2 2020 from the year-ago period, while the trailing twelve-month figure was $900000.0 through Jun 2020, up 12.5% year-over-year, with the annual reading at $900000.0 for FY2020, 12.5% up from the prior year.
  • Gains from Sales and Divestitures was $900000.0 for Q2 2020 at Myriad Genetics, roughly flat from $900000.0 in the prior quarter.
  • Over five years, Gains from Sales and Divestitures peaked at $900000.0 in Q4 2019 and troughed at $400000.0 in Q1 2016.
  • The 5-year median for Gains from Sales and Divestitures is $700000.0 (2017), against an average of $650000.0.
  • Year-over-year, Gains from Sales and Divestitures skyrocketed 1951.28% in 2016 and then changed 0.0% in 2017.
  • A 5-year view of Gains from Sales and Divestitures shows it stood at $400000.0 in 2016, then soared by 75.0% to $700000.0 in 2017, then grew by 14.29% to $800000.0 in 2018, then grew by 12.5% to $900000.0 in 2019, then changed by 0.0% to $900000.0 in 2020.
  • Per Business Quant, the three most recent readings for MYGN's Gains from Sales and Divestitures are $900000.0 (Q2 2020), $900000.0 (Q1 2020), and $900000.0 (Q4 2019).